GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Xoma Ltd. (XOMA) [hlAlert]

Rating:
Buy XOMA
down 97.16 %

Xoma Ltd. (XOMA) rated Buy by Pacific Growth Equities

Posted on: Tuesday,  Jul 29, 2008  8:25 AM ET by Pacific Growth Equities

Pacific Growth Equities rated Buy Xoma Ltd. (NASDAQ: XOMA) on 07/29/2008, when the stock price was $29.25. Since
then, Xoma Ltd. has lost 97.16% as of 11/27/2015's recent price of $0.83.
If you would have followed this Pacific Growth Equities's recommendation on XOMA, you would have lost 97.16% of your investment in 2677 days.

XOMA is a leader in the discovery, development and manufacture of therapeutic antibodies, with a therapeutic focus that includes cancer and immune diseases. XOMA has royalty interests in RAPTIVA, a monoclonal antibody product marketed worldwide to treat moderate-to-severe plaque psoriasis, and LUCENTIS, a monoclonal antibody product marketed worldwide to treat neovascular age-related macular degeneration. The company has built a premier antibody discovery and development platform that includes access to seven of the leading commercially available antibody phage display libraries and XOMA's proprietary Human Engineering and bacterial cell expression technologies. More than forty five companies have signed BCE licenses. XOMA's development collaborators include Lexicon Genetics, Inc., Novartis, and Schering-Plough Corporation. With a fully integrated product development infrastructure, XOMA's product development capabilities extend from preclinical sciences to product launch.

The Pacific Growth Equities research department strives to stay ahead of breaking news in some of the fastest moving and most complicated industries on Wall Street. Our research names are affected not only by economic swings but also by specific government regulations, new legislation, and often public opinion. Staying on top of every nuance allows us—and our clients—to lead and not follow. We take pride in providing incremental, value-added insights to the global institutional investment community. Our analysts are experienced in both industry and Wall Street, and are empowered to make the tough calls. Research insights are delivered quickly to the appropriate decision-makers so that important investment opportunities will not be lost. Any research analyst can call an impromptu meeting when news is breaking, to keep the sales force and management abreast of events that could impact the market both from a macro point of view and from one that is stock-specific.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
7/29/2008 8:25 AM Buy
None
29.25
as of 12/24/2008
1 Week down  -2.17 %
1 Month up  9.75 %
3 Months down  -31.81 %
1 YTD down  -27.41 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy